Yazar "Turhan A." seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The effect of cimetidine on plasma cholinesterase activity(1990) Ovul F.; Kosay S.; Eruyar S.; Erel L.; Turhan A.; Onat E.E.[No abstract available]Öğe Evaluation of INNO-LiPA Mycobacteria, INNO-LiPA Mycobacteria v2 and hsp65 sequencing for identification of the clinical nontuberculous mycobacterial isolates [Tüberküloz dişi mikobakteri izolatlarinin tanimlanmasinda INNO-LiPA Mycobacteria, INNO-LiPA Mycobacteria v2 ve hsp65 dizi analizinin karşilaştirilamasi](2005) Çavuşoglu C.; Turhan A.; Yaygin Y.E.; Karaca Derici Y.; Bilgiç A.In this study, polymerase chain reaction (PCR) reverse hybridization based line probe assays, INNO-LiPA Mycobacteria and INNO-LiPA Mycobacteria v2 (Innogenetics, Ghent, Belgium) and partial sequencing of hsp65 gene were evaluated for the identification of 29 clinical mycobacterial isolates. Unique hsp65 sequences identified during the study were deposited in EMBL (European Molecular Biology Laboratory) under accession numbers AY379074, AY379077, AY379075 and AY553874. All mycobacterial isolates were identified at the genus level on both LiPA assays, whereas 8 of 9 different known mycobacteria species (M.kansasii, M.gordonae, M.avium, M.intracellulare, M.chelonae, M.abscessus, M.fortuitum and M.peregrinum) were identified at species level with LiPA Mycobacteria v2. A clear correlation was found between the results of identifications obtained by the both LiPA assays, which targeted the 16S-23S rRNA ITS region, and DNA sequencing, which targeted the hsp65 gene. In conclusion, although LiPA Mycobacteria v2 could not identify all mycobacteria species, it may be especially useful for routine work in clinical laboratories, which are not capable of carrying out DNA sequencing.Öğe Investigation of anti-htlv-i/ii seroprevalence in healthy blood donors in Izmir region, Turkey [Izmir bölgesinde saglikli kan verícílerínde antí-HTLV-I/II seroprevalansinin araçtirilmasi](2010) Sertöz R.; Turhan A.; Bozkurt H.; Çamlioglu P.; Degrmenci A.; Aydinok Y.; Erensoy S.Almost 10-20 million people in the world are thought to be infected by human deltaretroviruses, namely human T-cell lymphotropic virus (HTLV) type I and II, recently. HTLV-I is endemic in southwestern Japan, the Caribbean and sub-Saharan Africa, whereas HTLV-II is more prevalent in intravenous drug addicts, and in American indián populations, endemically. HTLV-I is mainly responsible for adult T-cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), however, HTLVII is not clearly associated with a known clinical disease. Both viruses may be transmitted by sexual contact, parenteral route, whole blood transfusion and breast-feeding. In most of the countries [USA, Canada, South America, Caribbean, Japan, Taiwan and some Europe countries (France, UK, Ireland, Sweden, Denmark, The Netherlands, Portugal, Romania, Greece)] routine screening of anti-HTLV-I/II in blood donors is mandatory, however, there is no such practice in Turkey since seroepidemiologic data on HTLVI/II infections is insufficient. In this study, the seroprevalence of HTLV-I/II in healthy blood donors admitted to the blood bank of Ege University Medical Faculty Hospital, Izmir (located at Aegean region), was investigated to support data on the decision making process on routine screening of anti-HTLV-I/II in blood centers. Serum samples from 10.000 healthy blood donors (mean age: 32.6 years; 87.8% were male), who succeeded the donor history questionnaire, were included to the study, and HTLV-I/II antibodies were screened by a commercial enzyme immunoassay (ELISA) (Murex HTLVI-II, Murex Diagnostics, UK) method. Serum samples which were yielded reactive and borderline results were retested by ELISA, and repeated reactive/borderline results were then confirmed by HTLV-I/II confirmation test (INNO-LIA HTLV-I/II, lnnogenetics, Belgium). Seven samples yielded reactive/borderline reactive results by both ELISA lots, however, all of them were found negative by confirmatory test. According to our data HTLV-I/II infections are not endemic in Izmir region, and anti-HTLV-I/II screening of blood donors is not required in our blood center currently. Nevertheless, screening HIV which is very rare in prevalence among the donor population, is mandatory for blood donors in our country. Thus, even its prevalence is very low, much more comprehensive and multi-centered studies are necessary for making the decision of integrating HTLV-I/II in routine blood bank screening tests in Turkey.Öğe Plasma calcium, magnesium and phosphate levels during and after hypothermic cardiopulmonary bypass(1993) Kayaalti B.; Askar F.Z.; Turkoglu M.; Mutaf I.; Turhan A.; Certug A.[No abstract available]
